Which class of Antidysrhythmic drug delays repolarization and prolongs the effective refractory period?

Last updated: March 18, 2022

Summary

Antiarrhythmic drugs are used to prevent recurrent arrhythmias and restore sinus rhythm in patients with cardiac arrhythmias. These drugs are classified based on their electrophysiological effect on the myocardium. Antiarrhythmic drugs do not improve the survival of patients with non-life-threatening arrhythmias and may increase mortality, particularly in patients with structural heart disease. They are associated with severe adverse effects, primarily due to their proarrhythmic effects on the myocardium. Patients who have received an intravenous antiarrhythmic should be monitored closely with serial ECGs. Several classes of antiarrhythmics, including beta blockers, calcium channel blockers, amiodarone, cardiac glycosides, and lidocaine, also have other medical uses, which are discussed in their respective articles.

Overview

Classes of antiarrhythmic drugs [1][2]
ClassDrug group Mechanism of action Examples Use Adverse effects

Class I antiarrhythmics

Class IA antiarrhythmics
  • Fast sodium channel blockers
  • Reduce or even block conduction (negative dromotropy), particularly in depolarized tissue (e.g., during tachycardia)
  • State-dependent: the faster the heart rate (e.g., tachycardia), the greater the effect
    • Shorter diastole
    • Sodium channels spend less time in resting state
  • Decreases the slope of phase 0 depolarization
  • Stabilize membrane
  • Categorized into 3 subgroups based upon their effects on the Na+ channel and the action potential (AP) duration
  • Moderate blockage of Na+ channels(intermediate association/dissociation)
  • Prolong action potential (AP) duration (right shift)
  • Slow conduction velocity
  • Prolong effective refractory period (ERP) in ventricular APs
  • Weak blockade of the K+ channel
  • Quinidine
  • Procainamide
  • Disopyramide
  • Ajmaline
  • Paroxysmal supraventricular tachycardia (PSVT): AVNRT and AVRT
  • Ectopic SVTs
  • Antidromic AVRT and WPW (procainamide)
  • Atrial fibrillation (AFib) and atrial flutter
  • Ventricular arrhythmias
  • QT prolongation torsade de pointes (TdP)
  • Cinchonism: headache, hearing/vision loss, tinnitus, psychosis and cognitive impairment, associated with quinidine use
  • Thrombocytopenia
  • Procainamide
    • Drug-induced lupus erythematosus (reversible)
    • Drug fever
  • Disopyramide
    • Heart failure
    • Anticholinergic effects
Class IB antiarrhythmics
  • Weak blockade of Na+ channels (fast association/dissociation)
  • Shorten AP duration
  • Slow conduction velocity
  • No effect on or slight prolongation of ERP
  • Strongest effect on ischemic or depolarized cardiac Purkinje cells and ventricular myocardium
  • Lidocaine
  • Mexiletine
  • Phenytoin
  • Ventricular arrhythmias (especially following myocardial infarction)
  • Digitalis-induced cardiac arrhythmias
  • CNS: possible depression or excitation
    • Dizziness, nausea
    • Seizures
  • Cardiovascular: AV conduction block, ventricular extrasystoles
Class IC antiarrhythmics
  • Strong blockage of Na+ channels (slow association/dissociation) QRS prolongation
  • No to minimal effect on AP duration (no shift)
  • Slow conduction velocity
  • Extend duration of effective refractory period in both AV node and accessory tracts
  • ERP unaffected in cardiac Purkinje cells and ventricular myocardium
  • Flecainide
  • Propafenone
  • PSVT
  • AFib (cardioversion)
  • Atrial flutter
  • Last resort in refractory VT
  • Proarrhythmogenic: contraindicated following myocardial infarction
  • Possible QT prolongation due to increased QRS duration [3]
Class II antiarrhythmic drugs
  • Beta blockers
  • Inhibit β-adrenergic activation of adenylate cyclase cAMPCa2+ ↓ SA node and AV node activity
  • Prolong AV noderepolarization (AV node is highly sensitive to beta blockers) → prolongation of PR interval
  • Decrease slope of phase 4 in cardiac pacemaker cells → suppression of aberrant pacemakers
  • Slow conduction velocity
  • Metoprolol
  • Esmolol (short acting)
  • Propranolol
  • Atenolol
  • Timolol
  • Carvedilol
  • Sotalol
  • AFib (rate control)
  • Atrial flutter
  • PSVT
  • Premature ventricular contractions
  • Ventricular arrhythmias
  • Atrial premature beats [4]
  • AV block, bradycardia, heart failure
  • Exacerbation of asthma, COPD
  • Sedation, CNS depression, sleep alterations
  • Impotence
  • Hypoglycemia (can mask symptoms of hypoglycemia)
  • Hyperkalemia
  • Dyslipidemia (metoprolol)
  • Propanolol: may intensify vasospams in patients with preexisting vasospastic angina
  • Avoid in patients with concurrent cocaine use or pheochromocytoma.
    • Unopposed α1agonism → ↑ blood pressure, coronary and systemic vasoconstriction
    • Except for labetalol and carvedilol, which are nonselective α- and β-antagonists
Class III antiarrhythmic drugs
  • Potassium channel blockers
  • Inhibit delayed rectifier potassiumcurrents
  • Prolong QT interval
  • Prolong AP duration (reverse use dependence) and ERP
  • No effect on conduction velocity
  • Amiodarone (has class I, II, III, and IV properties; lipophilic)
  • Dronedarone
  • Sotalol
  • Bretylium
  • Ibutilide
  • Dofetilide
  • AFib (cardioversion and rhythm control)
  • Atrial flutter
  • Sotalol and amiodarone can be used to treat:
    • Supraventricular arrhythmias
    • Ventricular arrhythmias, e.g., tachycardia
  • QT prolongation TdP
  • Amiodarone
    • Cardiovascular
      • May cause heart failure, heart block, bradycardia, hypotension
      • Lowest risk of ventricular arrhythmia compared to other drugs in its class[5]
    • Pulmonary fibrosis
    • Thyroid dysfunction (hypo- or hyperthyroidism) due to high iodine content
    • Liver dysfunction
    • Neurologic side effects (e.g., peripheral neuropathy)
    • Can act as a hapten → bluish-gray deposits in cornea and skin → photosensitivity photodermatitis
    • Constipation
  • Sotalol: see “Beta blocker adverse effects
Class IV antiarrhythmic drugs
  • Calcium channel blockers
  • Inhibit slow calcium channels
  • Decrease slope of phase 0and 4 slower conduction velocity → increased ERP
  • Prolong AV node repolarization
  • Prolong PR interval
  • Verapamil
  • Diltiazem
  • Nifedipine
  • AFib (rate control)
  • Atrial flutter
  • Prophylaxis of nodal arrhythmias, e.g., PSVT
  • Multifocal atrial tachycardia
  • Hypertension (nifedipine)
  • Verapamil
    • AV block
    • Bradycardia
    • Depression of sinus node
    • Heart failure
    • Constipation
    • Flushing
    • Edema
  • Nifedipine
    • Headache
    • Flushing
    • Pitting edema
    • Reflex tachycardia
  • Diltiazem: adverse effects similar to those of both verapamil and nifedipine, but less prominent
Class V antiarrhythmic drugs
  • Variable mechanisms
  • Activates Gi protein → ↓ cAMP → deactivation of L-type Ca2+ channels → ↓ Ca2+ and ↑ K+ efflux → transient AV node block
  • Very short acting (∼ 15 sec)
  • Adenosine (drug)
  • Diagnosis and termination of certain forms of PSVT (e.g., AVNRT and orthodromic AVRT)
  • Chest pain
  • Flushing
  • Hypotension
  • Bronchospasm
  • Sense of impending doom
  • Effect weakened by adenosine receptor antagonists (e.g., theophylline, caffeine)
  • Decreases calcium influx → prevents early afterdepolarizations (EADs)
  • Magnesium sulfate
  • TdP
  • Digoxin toxicity
  • Hypotension
  • Asystole
  • Drowsiness
  • Flushing
  • Loss of reflexes
  • Respiratory depression
  • Inhibits Na+/K+-ATPases → higher intracellular Na+ concentration → reduced efficacy of Na+/Ca2+ exchangers → higher intracellular Ca2+ concentration → increased contractility and decreased heart rate
  • Digoxin
  • AFib
  • Atrial flutter
  • Chronic systolic heart failure
  • Nausea, vomiting
  • Abdominal pain
  • Blurry vision with a yellow tint and halos
  • Selectively inhibits If channel in the pacemaker cells of the SA node → prolongs slow depolarization (phase 4) → slows heart rate
  • Ivabradine
  • Chronic stable coronary heart disease in patients who cannot tolerate beta blockers
  • Chronic HFrEF
  • Vision changes: luminous phenomena (enhanced visual brightness)
  • Bradycardia
  • Hypertension

All antiarrhythmic drugs are also potentially proarrhythmic! Intravenous administration should only be performed with continuous cardiac monitoring!

I am Ambivalent about the QUEEn PROofreading my DISsertation”: Class IA antiarrhythmic drugs are QUEEnidine, PROcainamide, DISopyramide.
LInDO MEXIco Is the Best”: LIDOcaine and MEXIletine are class IB antiarrhythmic drugs.

I Can't Fail, Please”: Class IC antiarrhythmics are Flecainide, Propafenone.
I Am Sober, Doctor, for III days”: Ibutilide, Amiodarone, Sotalol, and Dofetilide are class III antiarrhythmic drugs.

Diltiazem and Verapamil Diminish conduction Velocity.

Class IB antiarrhythmic drugs work Best after myocardial infarction; class IC antiarrhythmic drugs are Contraindicated.

References:[6][7][8]

Other antiarrhythmic drugs

Adenosine (drug) [1]

  • Mechanism of action: activates Gi protein → inhibition of adenylate cyclase → ↓ cAMP → deactivation of L-type Ca2+ channels and activation of K+ channels → ↓ Ca2+ and ↑ K+ efflux → hyperpolarization transient AV node block (short-acting, ∼ 15 seconds) → acute termination of supraventricular tachycardia
  • Indications
    • Diagnosis and termination of certain forms of paroxysmal supraventricular tachycardias; (e.g., AVNRT and orthodromic AVRT) [9]
    • Diagnosis of underlying AFib in supraventricular tachyarrhythmias
    • Pharmacological stress test in myocardial perfusion scintigraphy [10]
  • Administration
    • Rapid bolus IV (very short half-life: < 10 seconds) [11]
    • May be administered repeatedly if the previous dose was unsuccessful
  • Adverse effects [12]
    • Chest pain, flushing, hypotension, bronchospasm
    • Sense of impending doom
    • AV block, asystole
  • Contraindications to adenosine
    • Pre-excitation syndromes: antidromic AVRT, WPW
    • AV block
    • Asthma
  • Interactions: Theophylline and caffeine weaken the effects of adenosine because they are adenosine receptor antagonists.

Avoid adenosine in patients with suspected pre-excitation tachycardia (e.g., WPW), because it may exacerbate the tachycardia via accessory pathway routes.

Digoxin

  • Mechanism of action: inhibits Na+/K+-ATPases → higher intracellular Na+ concentration → reduced efficacy of Na+/Ca2+ exchangers → higher intracellular Ca2+ concentration → increased contractility, decreased heart rate
  • Indications
    • AFib
    • Atrial flutter
    • Chronic systolic heart failure
  • Adverse effects: See “Cardiac glycoside poisoning”.

Magnesium sulfate [1][13]

  • Mechanism of action: decreases calcium influx → prevents early afterdepolarizations (EADs)
  • Indications
    • Torsade-de-pointes
    • Refractory ventricular tachyarrhythmias (e.g., polymorphic VT)
    • Digoxin intoxication
    • Eclampsia
    • Constipation
    • Tocolysis
  • Adverse effects
    • Hypotension
    • Asystole
    • Drowsiness
    • Flush
    • Loss of reflexes
    • Respiratory depression

Ivabradine [14]

  • Mechanism of action: selectively inhibits If channel in the pacemaker cells of the SA node → prolongs slow depolarization (phase 4) → slows heart rate
  • Indications: symptomatic stable coronary heart disease and congestive heart failure (NYHA II-IV) in patients who cannot tolerate beta blockers
  • Adverse effects
    • Vision changes: luminous phenomena (enhanced visual brightness)
    • Bradycardia
    • Hypertension

IVabradine slows depolarization in phase IV.

References

  1. Craig CR, Stitzel RE. Modern Pharmacology with Clinical Applications. Little, Brown Medical Division ; 1997
  2. Blomström-Lundqvist C, Scheinman MM, Aliot EM, et al. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary. Circulation. 2003; 108 (15): p.1871-1909. doi: 10.1161/01.CIR.0000091380.04100.84 . | Open in Read by QxMD
  3. Zehra Pinar K, Necati D, Tansel Ansal B, Ilgin K, Ferat K, Tolga C. Adenosine Stress Myocardial Perfusion Scintigraphy and Echocardiography Application with Same Infusion. International Journal of Clinical Cardiology. 2017; 4 (4). doi: 10.23937/2378-2951/1410106 . | Open in Read by QxMD
  4. McDowell M, Mokszycki R, Greenberg A, Hormese M, Lomotan N, Lyons N. Single‐syringe Administration of Diluted Adenosine. Academic Emergency Medicine. 2019; 27 (1): p.61-63. doi: 10.1111/acem.13879 . | Open in Read by QxMD
  5. Adenosine. https://www.drugs.com/pro/adenosine.html. Updated: January 1, 2017. Accessed: April 7, 2017.
  6. UpToDate, Lexicomp, Inc. Magnesium sulfate: Drug information. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. https://www.uptodate.com/contents/magnesium-sulfate-drug-information.Last updated: April 7, 2017. Accessed: April 7, 2017.
  7. Koruth JS, Lala A, Pinney S, Reddy VY, Dukkipati SR. The Clinical Use of Ivabradine. J Am Coll Cardiol. 2017; 70 (14): p.1777-1784. doi: 10.1016/j.jacc.2017.08.038 . | Open in Read by QxMD
  8. Razavi M. Safe and effective pharmacologic management of arrhythmias.. Texas Heart Institute journal. 2005; 32 (2): p.209-11.
  9. Oguayo KN, Oyetayo OO, Costa SM, Mixon TA. An Unusual Case of Flecainide-induced QT Prolongation Leading to Cardiac Arrest. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2014; 34 (5): p.e30-e33. doi: 10.1002/phar.1403 . | Open in Read by QxMD
  10. Manolis AS. Supraventricular Premature Beats. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. https://www.uptodate.com/contents/supraventricular-premature-beats.Last updated: March 14, 2016. Accessed: February 19, 2017.
  11. Giardina EG, Zimetbaum PJ. Monitoring and Management of Amiodarone Side Effects. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. https://www.uptodate.com/contents/monitoring-and-management-of-amiodarone-side-effects.Last updated: February 13, 2017. Accessed: April 5, 2017.
  12. Makielski JC. Myocardial action potential and action of antiarrhythmic drugs. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. https://www.uptodate.com/contents/myocardial-action-potential-and-action-of-antiarrhythmic-drugs.Last updated: September 4, 2013. Accessed: April 7, 2017.
  13. UpToDate. Flecainide: Drug information. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. https://www.uptodate.com/contents/flecainide-drug-information.Last updated: January 1, 2017. Accessed: October 10, 2017.
  14. UpToDate. Quinidine: Drug information. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. https://www.uptodate.com/contents/quinidine-drug-information.Last updated: January 1, 2017. Accessed: October 10, 2017.
  15. Le T, Bhushan V. First Aid for the USMLE Step 1 2015. McGraw-Hill Education ; 2014

What is a Class 3 Antidysrhythmic?

Class 3 antiarrhythmics are drugs that block cardiac tissue K channels Channels The Cell: Cell Membrane . The medications in this class include amiodarone. It increases the duration of ventricular and atrial muscle action by inhibiting potassium channels and voltage-gated sodium channels.

Which antiarrhythmic drug prolongs repolarization?

Intravenous amiodarone homogeneously prolongs ventricular repolarization in patients with life-threatening ventricular tachyarrhythmia.

Is a Class III antiarrhythmic drug which prolongs repolarization?

Antiarrhythmic Drugs Ibutilide is classified as a class III drug because it delays repolarization.

What are Class 4 antiarrhythmics used for?

Class IV antidysrhythmic drugs are used to treat: Atrial fibrillation and flutter (rapid and irregular heartbeats in the upper chamber of the heart) Paroxysmal supraventricular tachycardia (abnormal fast beating of the heart above the lower chambers) Hypertension (high blood pressure)